	US 12,138,252 B2
	Multikinase inhibitors of VEGF and TGF beta and uses thereof
Diane Tang-Liu, Las Vegas, NV (US); and Gerald Woodrow DeVries, San Clemente, CA (US)
Assigned to AIVIVA BIOPHARMA, INC., Las Vegas, NV (US)
Filed by AIVIVA BIOPHARMA, INC., Las Vegas, NV (US)
Filed on Dec. 29, 2020, as Appl. No. 17/137,195.
Application 17/137,195 is a division of application No. 16/485,221, abandoned, previously published as PCT/US2018/017810, filed on Feb. 12, 2018.
Claims priority of provisional application 62/457,929, filed on Feb. 12, 2017.
Prior Publication US 2021/0113535 A1, Apr. 22, 2021
This patent is subject to a terminal disclaimer.
Int. Cl. A61K 31/4402 (2006.01); A61K 9/00 (2006.01); A61K 31/47 (2006.01); A61K 31/496 (2006.01); A61P 17/02 (2006.01)

CPC A61K 31/4402 (2013.01) [A61K 9/0014 (2013.01); A61K 9/0019 (2013.01); A61K 31/47 (2013.01); A61K 31/496 (2013.01); A61P 17/02 (2018.01)]

18 Claims

1. A method of treating a disease or disorder, comprising administering at least one multikinase inhibitor to a mammal in need thereof, wherein the disease or disorder is rosacea, psoriasis, or atopic dermatitis, wherein the multikinase inhibitor is axitinib, nintedanib, lenvatinib, or a combination thereof.